Pharma Will Need To Embrace More Inward-Looking China
The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.
'Booming' China Pharma R&D Reaches New Peak
China has emerged as a major new force in global pharma R&D amid a "boom" in activity, with not one but two of its companies entering the top 25 by pipeline size for the first time.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.